Get started
DURECT CorporationDURECT CorporationDURECT Corporation

DURECT Corporation

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

DRRX trade ideas

Bullish Charts - Huge Earrings BeatDURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California. This morning Durect reported earrings that blew away Wall Street Estimates. Q2 EPS $0.07 Up From $(0.04) YoY, Sales $25 Million Beat $11.48 Million Estimate Sales more than doubled estimates. Daily Chart is Bullish Indicators are rising, Bullish Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:DRRXLong
by HotCharts
DRRX best Penny stocks for March The next one the next one is some of you pro bably remembered DRRX , these stocks for folks who are serious and want to trade price action and the truth is that as traitors we really couldn't careless we don't give a hoot about what happens to a dog after we take our price friend after me repeat after me who cares if it's be down afterwards am I right just fell out and validation and we don't even need it to be a good company we just need people to think that is a good company so we can exploit the opportunity of the run-up to the big spike the last fight for small in comparison but the last year was on an announcement that they had issued which will eventually culminating in a new approval date we are waiting for an announcement on a date or really needs to drop us to trade the price Trading quite low I just making sure that were getting any good deal or continuing to be a good day before you actually take your entry point that very important
NASDAQ:DRRXLong
by UnknownUnicorn6877177
1
Durect Corp bounces off Support DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
NASDAQ:DRRX
by DEXWireNews
DURECT CORP - NASDAQ: $DRRX FlaggingAfter breaking to higher ground a week ago on enormous volume, shares of DURECT CORP - NASDAQ:DRRX finds themselves consolidating the recent thrust in a Flag pattern on lower volume as we can observe from the Daily chart above. In addition, DRRX is now trading above all of its important moving averages 20/50/200 DMA's, which from a technical perspective, is healthy as well as constructive. Both investors/traders may want to continue to monitor the action closely in the days/weeks ahead as we believe that its only a matter of time before the stock comes up-and-out of its Flag with its sights set on greener pastures. Thus, investors/traders may want to put DRRX front-and-center on their radars as we're anticipating a potential move into the $1.40 - $1.60 zone (and potentially higher) should the stock pop out of its pattern within the days/weeks ahead. ****NOTE DURECT Corporation - NASDAQ:DRRX to Announce Second Quarter 2019 Financial Results on August 1, 2019 After Market Close ****
NASDAQ:DRRX
by InsiderFinancial
DRRX- Double bottom Fallen angel Long from 1.12 to 1.28 & 1.47 DRRX bouncing off its longterm support after a huge decline. Now it seems forming nice fallen angel formation with a higher low double bottom. We think it has good upside potential from here. * Trade Criteria * Date First Found- November 21, 2017 Pattern/Why- Fallen angel, Double bottom Entry Target Criteria- Break of $1.12 Exit Target Criteria- 1st Target $1.28, 2nd Target $1.47 Stop Loss Criteria- $ 0.97 Please check back for Trade updates. (Note: Trade update is little delayed here.)
NASDAQ:DRRXLong
by AcornWealthCorp
1